Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366322 · ClinicalTrials.gov registry record
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 124,879
- Enrollment target
NCT05366322: Completed study, sponsored by ModernaTX.
NCT05366322 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 124,879 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05366322 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 124,879 participants
- Enrollment target
Study Summary
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
Primary Outcome
Medically attended breakthrough COVID-19 diagnosis defined as a claim for COVID-19 in any setting (inpatient, outpatient, emergency room, urgent care, etc.).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124,879 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2022-03-21 |
What the finished NCT05366322 record still lists
NCT05366322 is an observational study that tracks outcomes without assigning an intervention. Its 124,879 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05366322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05366322 about?
NCT05366322 is a clinical study titled "A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults". The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
What is the current status of trial NCT05366322?
This trial is currently completed. The enrollment target is 124,879 participants. The study started on 2021-09-10. Estimated completion is 2022-03-21.
Who is sponsoring clinical trial NCT05366322?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI